ABOUT OVATION DIAGNOSTICS
Ovarian Cancer is a deadly disease, and generally is diagnosed too late. Our goal is to revolutionize the ways the disease is diagnosed.
Using a novel biomarker, we are developing non-invasive diagnostic tests that offer the promise of earlier and more accurate detection, enabling women to get the healthcare management they need, hopefully saving lives.
Ovation Diagnostics was formed in 2014 with a novel ovarian cancer biomarker technology licensed from the University of South Florida.
The research and initial clinical studies for this invention was done in collaboration with University of South Florida, MD Anderson Cancer Center and Moffitt Cancer Center.